BetterLife Pharma Inc. (BETRF)
USD 0.07
(0.0%)
USD 0.07
(0.0%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 | 324.74 Thousand CAD | 334.58% |
| 2023 | 74.72 Thousand CAD | -93.57% |
| 2022 | 1.16 Million CAD | -13.1% |
| 2021 | 1.33 Million CAD | -83.8% |
| 2020 | 8.25 Million CAD | -4.01% |
| 2019 | 8.59 Million CAD | 1715.3% |
| 2018 | 473.52 Thousand CAD | 172.39% |
| 2017 | 173.84 Thousand CAD | 17.2% |
| 2016 | 148.32 Thousand CAD | 9112.61% |
| 2015 | 1610.00 CAD | -77.54% |
| 2014 | 7167.00 CAD | 18.33% |
| 2013 | 6057.00 CAD | 57.57% |
| 2012 | 3844.00 CAD | -77.75% |
| 2011 | 17.27 Thousand CAD | -8.98% |
| 2010 | 18.97 Thousand CAD | -36.15% |
| 2009 | 29.72 Thousand CAD | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 Q3 | 509.52 Thousand CAD | 27.51% |
| 2024 FY | 324.74 Thousand CAD | 334.58% |
| 2024 Q4 | 324.74 Thousand CAD | -36.26% |
| 2024 Q1 | 722.32 Thousand CAD | 866.62% |
| 2024 Q2 | 399.59 Thousand CAD | -44.68% |
| 2023 Q1 | 359.4 Thousand CAD | -69.05% |
| 2023 FY | 74.72 Thousand CAD | -93.57% |
| 2023 Q4 | 74.72 Thousand USD | -73.23% |
| 2023 Q3 | 279.19 Thousand CAD | 11.39% |
| 2023 Q2 | 250.63 Thousand CAD | -30.26% |
| 2022 Q3 | 3.02 Million CAD | -46.66% |
| 2022 FY | 1.16 Million CAD | -13.1% |
| 2022 Q4 | 1.16 Million CAD | -61.65% |
| 2022 Q2 | 5.67 Million CAD | 296.06% |
| 2022 Q1 | 1.43 Million CAD | 7.28% |
| 2021 Q4 | 1.33 Million CAD | -89.56% |
| 2021 Q2 | 6.64 Million CAD | -2.12% |
| 2021 FY | 1.33 Million CAD | -83.8% |
| 2021 Q1 | 6.78 Million CAD | -17.73% |
| 2021 Q3 | 12.79 Million CAD | 92.62% |
| 2020 Q3 | 16.03 Million CAD | -10.56% |
| 2020 FY | 8.25 Million CAD | -4.01% |
| 2020 Q1 | 9.54 Million CAD | 11.09% |
| 2020 Q2 | 17.92 Million CAD | 87.76% |
| 2020 Q4 | 8.25 Million CAD | -48.55% |
| 2019 Q4 | 8.59 Million CAD | -7.46% |
| 2019 Q3 | 9.28 Million CAD | -6.04% |
| 2019 Q2 | 9.88 Million CAD | -12.69% |
| 2019 FY | 8.59 Million CAD | 1715.3% |
| 2019 Q1 | 11.32 Million CAD | 2290.99% |
| 2018 Q4 | 473.52 Thousand CAD | -31.03% |
| 2018 Q3 | 686.56 Thousand CAD | 1428.58% |
| 2018 Q2 | 44.91 Thousand CAD | -50.43% |
| 2018 Q1 | 90.61 Thousand CAD | -47.88% |
| 2018 FY | 473.52 Thousand CAD | 172.39% |
| 2017 Q4 | 173.84 Thousand CAD | -43.34% |
| 2017 Q2 | 23.04 Thousand CAD | -66.58% |
| 2017 FY | 173.84 Thousand CAD | 17.2% |
| 2017 Q1 | 68.93 Thousand CAD | -53.52% |
| 2017 Q3 | 306.79 Thousand CAD | 1231.52% |
| 2016 Q3 | 208.17 Thousand CAD | -23.42% |
| 2016 FY | 148.32 Thousand CAD | 9112.61% |
| 2016 Q2 | 271.83 Thousand CAD | 676.19% |
| 2016 Q1 | 35.02 Thousand CAD | 2075.22% |
| 2016 Q4 | 148.32 Thousand CAD | -28.75% |
| 2015 Q4 | 1610.00 CAD | -79.62% |
| 2015 FY | 1610.00 CAD | -77.54% |
| 2015 Q3 | 7901.00 CAD | -31.35% |
| 2015 Q2 | 11.5 Thousand CAD | 70.86% |
| 2015 Q1 | 6736.00 CAD | -6.01% |
| 2014 Q3 | 14.31 Thousand CAD | 110.0% |
| 2014 Q2 | 6818.00 CAD | -66.94% |
| 2014 Q1 | 20.62 Thousand CAD | 240.48% |
| 2014 FY | 7167.00 CAD | 18.33% |
| 2014 Q4 | 7167.00 CAD | -49.94% |
| 2013 Q4 | 6057.00 CAD | -8.53% |
| 2013 Q1 | 7144.00 CAD | 85.85% |
| 2013 Q2 | 6715.00 CAD | -6.01% |
| 2013 FY | 6057.00 CAD | 57.57% |
| 2013 Q3 | 6622.00 CAD | -1.38% |
| 2012 Q1 | 60.66 Thousand CAD | 251.15% |
| 2012 Q2 | 20.92 Thousand CAD | -65.51% |
| 2012 Q3 | 7423.00 CAD | -64.52% |
| 2012 Q4 | 3844.00 CAD | -48.22% |
| 2012 FY | 3844.00 CAD | -77.75% |
| 2011 FY | 17.27 Thousand CAD | -8.98% |
| 2011 Q1 | 6198.00 CAD | -67.34% |
| 2011 Q2 | 2744.00 CAD | -55.73% |
| 2011 Q3 | 1900.00 CAD | -30.76% |
| 2011 Q4 | 17.27 Thousand CAD | 809.21% |
| 2010 FY | 18.97 Thousand CAD | -36.15% |
| 2010 Q4 | 18.97 Thousand CAD | 0.0% |
| 2009 FY | 29.72 Thousand CAD | 0.0% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| Eiger BioPharmaceuticals, Inc. | 38.84 Million USD | 99.164% |
| Nanobac Pharmaceuticals, Incorporated | 7.21 Million USD | 95.502% |
| SQZ Biotechnologies Company | 107.18 Million USD | 99.697% |
| Evofem Biosciences, Inc. | 10.55 Million USD | 96.923% |
| Santhera Pharmaceuticals Holding AG | 130.21 Million USD | 99.751% |
| Mesoblast Limited | 667.9 Million USD | 99.951% |
| Propanc Biopharma, Inc. | 72.36 Thousand USD | -348.761% |
| Genus plc | 1.02 Billion USD | 99.968% |
| VioQuest Pharmaceuticals, Inc. | 1.35 Million USD | 76.093% |
| CNBX Pharmaceuticals Inc. | 499.03 Thousand USD | 34.926% |
| Marizyme, Inc. | 22.01 Million USD | 98.525% |
| ContraFect Corporation | 20.67 Million USD | 98.43% |
| Nymox Pharmaceutical Corporation | 627 Thousand USD | 48.206% |
| PsyBio Therapeutics Corp. | 390.36 Thousand USD | 16.81% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 382.17 Thousand USD | 15.027% |
| Intellipharmaceutics International Inc. | 1.43 Million USD | 77.323% |
| AXIM Biotechnologies, Inc. | 4.14 Million USD | 92.167% |
| MultiCell Technologies, Inc. | 126.22 USD | -257185.692% |
| Accustem Sciences Inc. | 939.68 Thousand USD | 65.441% |
| RVL Pharmaceuticals plc | 128.51 Million USD | 99.747% |
| EV Biologics, Inc. | 431.71 Thousand USD | 24.778% |
| Q BioMed Inc. | 3.51 Million USD | 90.762% |
| Emmaus Life Sciences, Inc. | 35.17 Million USD | 99.077% |
| Neon Bloom, Inc. | 770.64 Thousand USD | 57.86% |
| Mosaic ImmunoEngineering Inc. | 261.27 Thousand USD | -24.292% |
| Biomind Labs Inc. | 73.81 Thousand USD | -339.922% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Pharming Group N.V. | 462.85 Million USD | 99.93% |
| Oncotelic Therapeutics, Inc. | 30.01 Million USD | 98.918% |
| Skye Bioscience, Inc. | 11.94 Million USD | 97.28% |
| Therapeutic Solutions International, Inc. | 3.31 Million USD | 90.198% |
| THC Farmaceuticals, Inc. | 2.74 Million USD | 88.175% |
| Arch Therapeutics, Inc. | 1.95 Million USD | 83.416% |
| IMV Inc. | 31.33 Million USD | 98.964% |
| Acro Biomedical Co., Ltd. | 687.48 Thousand USD | 52.763% |
| Curative Biotechnology, Inc. | 2.6 Million USD | 87.525% |
| GB Sciences, Inc. | 103.44 Thousand USD | -213.94% |
| Alpha Cognition Inc. | 2.45 Million USD | 86.757% |
| HST Global, Inc. | 1526.00 USD | -21180.865% |
| CSL Limited | 38.02 Billion USD | 99.999% |
| Halberd Corporation | 10.13 Thousand USD | -3105.468% |
| Enzolytics Inc. | 361.7 Million USD | 99.91% |
| Resverlogix Corp. | 8.11 Million USD | 95.998% |
| Affymax, Inc. | 7.44 Million USD | 95.637% |
| SYBLEU INC | 330.46 Thousand USD | 1.731% |
| Nuo Therapeutics, Inc. | 1.87 Million USD | 82.707% |
| argenx SE | 4.54 Billion USD | 99.993% |
| MetaStat, Inc. | - USD | -Infinity% |
| Northwest Biotherapeutics, Inc. | 27.94 Million USD | 98.838% |
| Enzon Pharmaceuticals, Inc. | 47.7 Million USD | 99.319% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| RespireRx Pharmaceuticals Inc. | 22.78 Thousand USD | -1325.512% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | 8.94 Million USD | 96.371% |
| AVAX Technologies, Inc. | 7.37 Million USD | 95.598% |
| Zenith Capital Corp. | 7410.00 USD | -4282.537% |
| Genscript Biotech Corporation | 3.38 Billion USD | 99.99% |
| Ember Therapeutics, Inc. | 184.00 USD | -176392.391% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | 321.8 Thousand USD | -0.914% |
| WPD Pharmaceuticals Inc. | 261.36 Thousand USD | -24.25% |
| American Oriental Bioengineering, Inc. | 446.3 Million USD | 99.927% |
| Provectus Biopharmaceuticals, Inc. | 1.44 Million USD | 77.586% |
| Adynxx, Inc. | - USD | -Infinity% |
| Helix BioMedix, Inc. | 3.02 Million USD | 89.265% |
| GlobeStar Therapeutics Corporation | - USD | -Infinity% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Capstone Therapeutics Corp. | 52.7 Million USD | 99.384% |
| Cotinga Pharmaceuticals Inc. | 927.96 Thousand USD | 65.004% |
| BioStem Technologies, Inc. | 14.56 Million USD | 97.77% |
| ONE Bio Corp. | 70.08 Million USD | 99.537% |
| Reve Technologies, Inc. | 57.09 Thousand USD | -468.792% |
| Burzynski Research Institute, Inc. | 2310.00 USD | -13958.268% |
| Wesana Health Holdings Inc. | 987.96 Thousand USD | 67.13% |
| Agentix Corp. | 261.39 Thousand USD | -24.237% |
| LadRx Corporation | 2.3 Million USD | 85.929% |
| Cell Source, Inc. | 195.17 Thousand USD | -66.39% |
| ProtoKinetix, Incorporated | 480.55 Thousand USD | 32.423% |
| Regen BioPharma, Inc. | 353.61 Thousand USD | 8.164% |
| Regen BioPharma, Inc. | 353.61 Thousand USD | 8.164% |
| NovAccess Global Inc. | 62.24 Thousand USD | -421.697% |
| Endonovo Therapeutics, Inc. | 639.65 Thousand USD | 49.231% |
| Itoco Inc. | 1.4 Million USD | 76.805% |
| Rasna Therapeutics, Inc. | 95.65 Thousand USD | -239.49% |
| Pathfinder Cell Therapy, Inc. | 106 Thousand USD | -206.364% |
| Kadimastem Ltd | 2.3 Million USD | 85.906% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Institute of Biomedical Research Corp. | 76.35 Thousand USD | -325.316% |
| CytoDyn Inc. | 11.13 Million USD | 97.084% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | 142.97 Thousand USD | -127.14% |
| Mobile Lads Corp. | 52.00 USD | -624411.538% |
| NanoSphere Health Sciences Inc. | 17.88 Thousand USD | -1716.253% |
| Qrons Inc. | 420.00 USD | -77220.476% |
| Alseres Pharmaceuticals, Inc. | 385.47 Thousand USD | 15.753% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| Nascent Biotech, Inc. | 552.12 Thousand USD | 41.182% |
| Rebus Holdings, Inc. | 5000.00 USD | -6394.92% |
| ImmunoCellular Therapeutics, Ltd. | 409.42 Thousand USD | 20.682% |
| International Stem Cell Corporation | 5.39 Million USD | 93.975% |
| Bioxytran, Inc. | 137.63 Thousand USD | -135.942% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 15 Million USD | 97.835% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | - USD | -Infinity% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 16.57 Million USD | 98.041% |
| Adhera Therapeutics, Inc. | 79 Thousand USD | -311.071% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 864.67 Thousand USD | 62.443% |
| Innovation Pharmaceuticals Inc. | 7.51 Million USD | 95.68% |
| Neutra Corp. | 2851.00 USD | -11290.6% |
| Windtree Therapeutics, Inc. | 32.4 Million USD | 98.998% |
| PureTech Health plc | 693.97 Million USD | 99.953% |
| Coeptis Therapeutics, Inc. | 8.07 Million USD | 95.976% |
| IXICO plc | 15.84 Million USD | 97.95% |
| IntelGenx Technologies Corp. | 8.28 Million USD | 96.079% |
| Gelesis Holdings, Inc. | 103.32 Million USD | 99.686% |
| CSL Limited | 38.02 Billion USD | 99.999% |
| Cellectis S.A. | 333.99 Million USD | 99.903% |